PSBC Provincial Perinatal Guidelines Committee
Sample Guideline Template
N427 Synthesis Project – UBC School of Nursing
February 2014
Development Committee Members:
Thayanthi Tharmaratnam, Sarika Rama, Chelsea MacAulay
Page 1 of 12
February 2014
TABLE OF CONTENTS
1.0
INTRODUCTION.....................................................................................................2
2.0
RISK FACTORS .....................................................................................................2
3.0
ASSESSMENT .......................................... ERROR! BOOKMARK NOT DEFINED.
4.0
CLINICAL MANAGEMENT ....................................................................................4
5.0
OTHER ISSUESIN THE MANAGEMENT OF JAUNDICE .....................................5
6.0
STRATEGIES FOR DECREASING INCIDENCE...................................................6
7.0
UNIVERSAL SCREENING .....................................................................................7
8.0
GLOSSARY ............................................................................................................7
REFERENCES ..................................................................................................................8
DEVELOPMENT COMMITTEE MEMBERS......................................................................9
APPENDICES..................................................................................................................10
APPENDIX 1:
Potential Algorithm for management and follow-up according to to predischarge
bilirubin measurement (Lease & Whalen, 2010)....................................................... 10
APPENDIX 2:
Guidelines for detection, management, and prevention of hyperbilirubinemia in
term and late preterm newborn infants (Canadian Paediatrics Society's
Community Paediatrics Committee and the College of Family Physicians of
Canada) ........................................................................................................................ 11
APPENDIX 3:
Management of hyperbilirubinemia in Newborn Infant 35 or more weeks of
gestation (American Academy of Pediatrics, 2004)................................................. 11
APPENDIX 4:
Universal bilirubin screening for severe neonatal hyperbilirubinemia (Bhutani,
2010). .......................................................................................................................................... 11
Page 2 of 12
February 2014
1.0
Introduction
Hyperbilirubinemia (jaundice) is a common condition occurring in newborns. Jaundice occurs in 60% of term
infants and nearly all preterm infants (Watson, 2009). Jaundice has potential devastating effects such as
progression to kernicterus. Kernicterus is a rare condition but cases are continuing to occur as a result of
imprecise assessments, insufficient screening protocols and early discharge from hospitals (Newman, 2009;
Watson, 2009 ). Nurses must be vigilant when identifying and monitoring infants at risk and implementing
treatments when needed, to help reduce the potential negative impacts of untreated jaundice (Watson, 2009).
2.0
Risk Factors
RISK FACTORS OF PHYSIOLOGICAL JAUNDICE
o Major Clinical Risk Factors:

GA 35-36 weeks (Academy of Pediatrics, 2004).

Rh isoimmunization, ABO or other blood incompatibles (Watson, 2009).

Previous sibling with neonatal jaundice requiring phototherapy (Ives, 2011).

Exclusive and insufficient breast milk transfer (Bhutani, Vilms & Hamerman-Johnson, 2010).

Visible jaundice in the first 24 hrs of life ("National institute for," 2010).

Heavy bruising from delivery: old RBC's underneath the skin resulting in increased bilirubin
production (Ives, 2011).

Repeated attempts at vacuum extraction (Bhutani, Vilms & Hamerman-Johnson, 2010).

Cephal-hematoma/significant bruising (Ives, 2011).

Ethnicity (East Asian) (Bhutani, Vilms & Hamerman-Johnson, 2010).

Jaundice prior to 24 hours (Ives, 2011).
o Minor Clinical Risk Factors:

Male gender (Bhutani, Vilms & Hamerman-Johnson, 2010).

Macrosomic babe with GD mother (Ives, 2011).

Maternal age >25 (Bhutani, Vilms & Hamerman-Johnson, 2010).

GA 37-38 weeks (Bhutani, Vilms & Hamerman-Johnson, 2010).

Jaundice observation prior to discharge.

Pre-discharge TSB/tcb in high zone.
RISK FACTORS OF PATHOLOGICAL JAUNDICE
o General Risk Factors:

Jaundice appearing in the first 24 hrs of life jaundice in a sick neonate (Bhutani, Vilms &

Hamerman-Johnson, 2010).

Rapidly rising serum bilirubin.

Increased production of bilirubin load on the liver.

Immune-mediated hemolytic anemia.

Prolonged jaundice more than 14 days in term infant; more than 21 days in preterm infants
("National institute for," 2010).

Conjugated serum bilirubin more than 25 umol/litre ("National institute for," 2010).

Pale, chalky stools and dark urine (Bhutani, Vilms & Hamerman-Johnson, 2010).
o Hemolytic Risk Factors:

Red cell enzyme defects: glucose-6-phosphate dehydrogenase deficiency, pyruvate kinase
deficiency, other erythrocyte enzyme deficiencies (Watson, 2009).

Red cell membrane defects (Watson, 2009).

Hemolytic disease (Watson, 2009).

Hemoglobinopathies (Watson, 2009).

Unstable hemoglobin levels (Watson, 2009).

Disseminated intravascular coagulation (DIC) (Watson, 2009).

Extravasation of blood, hematomas and pulmonary/abdominal/cerebral/other occult hemorrhage
(Watson, 2009).

Increased enterohepatic circulation (Watson, 2009).

Polycythemia (Ives, 2011).
o Heritable/Genetic Risk Factors:

Hereditary spherocytosis, elliptocytosis, pyropoikiloctosis, stomatocytosis (Watson, 2009).

Congenital heinz body hemolytic anemia (Watson, 2009).

Pyloric stenosis (Watson, 2009).
Page 3 of 12
February 2014
o Metabolic Risk Factors:

Inborn errors of metabolism:
• Criglr-Najjar syndrome, types I and II (Watson, 2009).
• Gilbert synfrom (Watson, 2009).
• Galactosemia (Watson, 2009).
• Tyrosinemia (Watson, 2009)Hypermethionemia (Watson, 2009).
• Hypothyroidism (Ives, 2011)
• Hypoituitarism (Ives, 2011).
o Increased absorption of bilirubin from the GI tract:

Small or large bowel obstruction or ileum.

Decreased clearance.
BREASTFEEDING JAUNDICE
o Early Breastfeeding Jaundice:

Usually begins within 2-4 days of life (Watson, 2009).

Peaks between day 3 and 6 of life (Watson, 2009).

Related to the process/pattern of breastfeeding (Watson, 2009).

Causes: dehydration, poor caloric intake and increased enterohepatic circulation (Watson, 2009)
o Late Breast Milk Jaundice:
 Appears around 4-7 days of life (Watson, 2009).
 Peaks between day 5 and 15 of life (Watson, 2009).
 No confirmed theories to explain this pattern of jaundice; speculated that substances in breast milk
may block proteins in the liver responsible for breakdown of bilirubin (Watson, 2009).
3.0
Assessment
COLOUR
Kramer’s 5-point scale is commonly used by nurses to describe the extent of infant jaundice (Keren,
Tremont, & Luan, 2009). The scale’s score is based on cephalocaudal progression of an infant’s
jaundice, with facial jaundice being a score of 1 and increasing numerically as jaundice extends toward
the feet. This score should not be the used as a primary means of assessing for jaundice, as research
shows poor correlation between assessments based on the Kramer Scale and measured bilirubin
values. Extra caution should be taken with the examination of late preterm infants, as they are at an
increased risk of developing hyperbilirubinemia and the Kramer Scale is particularly limited with this
population (Keren et al., 2009). The TSB range associated with progression through the 5 zones is as
follows:
To assess the colour of the skin, observe after blanching by pressure from the thumb. This should be performed
in a well-lit room, or in natural light if performed in the home. It should be noted that prolonged exposure to direct
or indirect sunlight can bleach a newborn’s skin, making it more difficult to assess for jaundice (Lease & Whalen,
2010).
Page 4 of 12
February 2014
AGE
Jaundice before 24 hours or after 10 days of life is always pathological, and the cause should be investigated
prior to initiating any treatment. Jaundice that occurs between 24 hours to 10 days of life is determined to be
pathological or physiological by plotting the age of the infant against their total bilirubin levels on the Bhutani Risk
Graph. Knowing an infant’s risk zone can be beneficial when deciding to initiate treatment (Lease & Whalen,
2010).
FEEDING
Feeding helps newborns pass bilirubin in their stools. After the first 1-2 days of life, newborns should be
breastfed 8 or more times in a 24 hour period. As the bilirubin levels increase, the newborn may become more
lethargic and have a decreased desire to feed. If the newborn is sleepy during feeds, utilize waking techniques to
keep them active (eg, removing a layer of clothes, tickling feet, talking to baby) (Perinatal Services BC, 2013).
HYDRATION/INTAKE
Adequate intake during feeds can be determined by assessing the following (Perinatal Services BC, 2013):
•
•
•
•
•
Signs and symptoms of dehydration (eg: skin turgor, moistness of mouth/mucous membranes).
Newborn weight loss
Energy levels.
Feeding pattern/behaviors.
Elimination (see guide below, based on breastfed infant). A newborn suffering from jaundice typically
experiences increased frequency of stools, which may be loose, greenish in colour, and explosive
(Perinatal Services BC, 2013).
# of
Stools/Day
# of Wet
Diapers/Day
4.0
Day 1 (0-24hr )
at least 1
meconium
at least 1
Day 2 (24-48hr)
at least 1 meconium or 1
transitional stool
1-2
Day 3 (48-72hr)
3-4 transitional
stools
2-3
Day 4 (72-96hr)
3-4 transitional
stools
3-5
Day 5 (96-120hr)
3-6 yellow, seedy
stools
4-6
Clinical Management
Clinical management is aimed at avoiding bilirubin encephalopathy and its long term neurological complications.
Adequate hydration is an important consideration in the infant with moderate to high bilirubin levels.
Fundamental to management is a good history and physical examination, together with appropriate investigations
including:
•
•
•
•
Unconjugated and conjugated bilirubin.
Blood group determination with a direct antibody test (coomb’s test).
Hemoglobin and hematocrit.
Other lab investigations (eg. T4, g6pd) may be required depending on the patient assessment.
Once the serum bilirubin reaches “risk” levels, the standard treatment is the use of phototherapy and/or
exchange transfusion. Several expert bodies have developed guidelines to assist care providers determine the
appropriate time to implement each therapy as well as how to provide the therapy most effectively.The most
common guidelines utilized in risk identification and management of hyperbilirubinemia are listed in the
appendices.
Page 5 of 12
February 2014
5.0
Other Issues in the Management of Jaundice
BREASTFEEDING AND PHOTOTHERAPY
Interruption of breastfeeding is not indicated; the latest research emphasizes family-centred approach to have the
infant breastfeeding while phototherapy is being delivered (Szucs & Rosenman, 2013; Willis, Hannon, Scrimshaw,
2002). An adequate intake of milk minimizes the bilirubin level by stimulating bowel emptying. Encourage
frequent and effective breastfeeding (at least 8X in 24 hours) (Stokowski, 2011; American Academy of Pediatrics,
2004). Breastfeeding may be interrupted for diagnostic or therapeutic purposes when the bilirubin levels are high
and there is a risk of an exchange transfusion. Should this occur, the following is advised:
•
•
•
•
•
Continue phototherapy.
Consider discontinuing breastfeeding for 24 hours or alternate breastfeeding with formula feeding if fluid
intake is a concern.
Offer positive support for breastfeeding by encouraging the maintenance of lactations by using a breast
pump or manual expression during the period of interrupted breastfeeding.
Family centre approaches encourages kangaroo care where care provider offers skin-to-skin and
breastfeeds while phototherapy treatment is given (Szucs & Rosenman, 2013).
Routine supplementation of breastfed infants with water or dextrose water is not recommended
(Canadian Paediatric Society, 2007).
Figure 3: Kangaroo care where the mother is placed skin to skin with her baby during phototherapy treatment and ‘biliblankets’. Eyeshields are worn by
both. (Szucs & Rosenman, 2013).
DAYLIGHT TREATMENT
Exposing infants to indirect or direct sunlight via a window has been a long standing practice. (Stokowski, 2011)
Controlled studies on this treatment have not been done in Western countries. Mild jaundice requires no sunlight
exposure, as it sends a false note to parents that their baby has a significant problem when in fact the infant does
not. Changes in the beliefs of sunlight exposure need to change to avoid long term risk of skin cancer. (Harrison,
Nikles, & Nowak, 2013) If an infant has jaundice that needs treatment according to accepted guidelines then it
should be investigated further.
FIBROPTIC TREATMENT
Use of fibroptic or “bili blankets” are commonly used as a “double” phototherapy treatment in additional to the
conventional treatment (. Studies have found that fibroptic and conventional phototherapy are more effective than
conventional phototherapy alone. No conclusion could be made on the superiority of one fibroptic device over
another. Studies have found that fibroptic devices do not interfere more with infant care or on parent-child
bonding. At this time, “bili blankets” are still recommended not to be used alone to treat non-physiologic causes
of jaundice or those infants at risk of requiring an exchange transfusion.
HOME PHOTOTHERAPY
There are few articles in the literature that address this issue in the North American context especially pertaining
to Canada. One Cochrane review compared home versus hospital phototherapy treatment found that home
treatment is the same in efficacy within the first 24 hours, but treatment requiring more duration were not as
effective and required longer duration compare to hospital based treatment Malwade & Jardine, 2012). On the
other hand, home treatment provided more parent-infant bonding time (Malwade & Jardine, 2012). With increase
use of conventional hospital treatments there have been few implementation of this method in communities in
Canada. To date there are no published evidence-based guidelines on the use of home phototherapy in Canada.
Page 6 of 12
February 2014
PHOTOTHERAPY AND EYE SHIELDS
Eye shields have been recommended for use to protect the infant’s eye from phototherapy damage. If using eye
shields, they should be removed for short periods to encourage interactions with careproviders, should not be put
on too tightly as the pressure can damage the newborn’s eyelids (Szucs & Rosenman, 2013; Stokowski,2011).
PROPHYLATIC PHOTOTHERAPY FOR PREMATURE/VERY LOW-WEIGHT INFANT
A recent Cochrane review has looked at prophylactic phototherapy treatment that has found prophylactic
treatment prevents serum bilirubin levels from increasing when treatment is given within 36 hours of birth for
preterm and/or very low weight infant, but further research is required to understand long term outcomes on the
brain and central nervous system development and other areas by using prophylactic phototherapy treatment.
(Okwundu, Okoromah, & Shah, 2013)
Clinical Evaluation:
•
Serum bilirubin levels at which phototherapy is initiated.
•
Bilirubin levels at which the infant is readmitted.
•
Numbers of readmissions for jaundice.
6.0
Strategies for Decreasing Incidence
LABOUR AND DELIVERY
•
•
Avoid trauma during labor and delivery.
Blood typing: all pregnant women should be tested for ABO and Rh blood types and have a serum
screen for unusual isoimmune antibodies (ECRI Institute, 2010).
BREASTFEEDING
•
•
•
•
Provide early assistance education and support for breastfeeding.
Encourage mothers to breastfeed 8-12 times a day (ECRI Institute, 2010).
Assess adequate intake of newborn.
Do not supplement with water or dextrose because that may result in bilirubin levels rising. If
supplementation is necessary due to inadequate intake, the mother should pump her breasts and give
expressed breast milk, donor milk and/or formula.
ASSESSMENTS
•
•
Visual inspection includes checking naked baby in bright and natural light (unreliable under artificial light
and once phototherapy has started). Be aware that visual inspections are not accurate and may often
lead to errors especially in darker babies (Ives, 2011).
Visual assessment should be done whenever vital signs are taken but no less than every 8-12 hours for
at risk babies (Bhutani, Vilms & Hamerman-Johnson, 2010).
PARENTAL EDUCATION
•
•
Teach parents how to recognize clinical jaundice. Education regarding factors that influence the
development of jaundice, how to check baby for jaundice, what to do if they suspect jaundice,
importance of checking baby's diaper for dark urine or chalky stools. ("National institute for," 2010).
Ensure parental education regarding signs of adequate hydration and feeding.
DISCHARGE/ FOLLOW-UP
•
•
•
•
Perform risk assessment before discharge by recognizing major risk factors (ECRI Institute, 2010)
Referral for postpartum follow up in community after discharge if risk factors exist.
Initiate early postpartum follow-up once discharged from hospital. All infants discharged prior to 48 hours
of age should be evaluated by a health care professional within 48 hours after discharge (if concerned
with babe) or risk factor identified (ECRI Institute, 2010).
Consider referral to lactation consultant or community health clinics if mother needs additional
breastfeeding support ("National institute for," 2010).
SCREENING
•
•
•
•
Serum bilirubin levels must be measured for appropriate clinical management .
Measure TSB or TCB if jaundice occurs in the first 24 hours (Academy of Pediatrics, 2004)
Interpret bilirubin levels according to infant age in hours (ECRI Institute, 2010)
TCB levels can be unreliable during phototherapy or with exposure to sunlight because of the bleaching
effect of light on the skin (Academy of Pediatrics, 2004).
Page 7 of 12
February 2014
•
7.0
Accuracy is not enhanced by the use of icoerometeres (ECRI Institute, 2010).
Universal Screening
In 2007, the Canadian Pediatric Society made the recommendation that all infants receive a TSB or
TcB measurement either at 72 hours of age or at time of discharge. TcB measurements are nonevasive, and reduce the opportunity for infant skin infections. TcB results are available to nurses
instantly, without having to wait for laboratory results. Despite these advantages, TcB measurements
often need to be verified by a TSB measurement, especially if an infant TcB vaule is high or if multiple
risk factors exist. A TSB measurement is considered to be the gold standard in assessing jaundice and
determining the course of treatment, especially when considering either the initiation or discontinuation
of phototherapy. Universal TSB screening could be beneficial as the trend of early postpartum
discharge progresses; allowing for quicker turn around in lab results and follow-up care as they
become more routine in care provision, and limiting the need for later interventions such as
readmission for phototherapy treatments.
8.0
Glossary
• Full-Term Infant: An infant born after the completion of the 36th week of gestation (ie: minimum gestational age
of 37+0 at birth) (Engle, 2006).
• Hyperbilirubinemia: Elevated amounts of bile pigment, or bilirubin, in the blood (Canadian Pediatric Society,
2007).
• Immune-Mediated Hemolytic Anemia: an immune mediated destruction of red blood cells, indirectly resulting in
hyperbilirubinemia (Makadia, Siddaiahgari & Latha, 2013).
• Kernicterus: an accumulation of bilirubin in the gray matter of CNS causing neurological damage.
• Late Pre-Term Infant: An infant born after the completion of the 34th week of gestation (ie: minimal gestational
age of 35+0 at birth) and before the commencement of the 37th week of gestation (ie: maximum gestational
age of 36+6 at birth) (Engle, 2006).
• Pathological Jaundice: Jaundice that begins in infants before 24 hours of life, or after 10 days of life, or severe
jaundice that occurs between 24 hours to 10 days of life (Lease & Whalen, 2010).
• Physiological Jaundice: A common and normally self-limiting condition seen in infants that occurs after 24
hours of age and can last as long as two weeks (Lease & Whalen, 2010).
Page 8 of 12
February 2014
References
American Academy of Pediatrics (2004). Management of hyperbilirubinemia in the newborn infant 35 or
more weeks of gestation. PEDIATRICS, 114(1), 297-316. Retrieved from
http://pediatrics.aappublications.org/content/114/1/297.full.pdf
Bhutani, V. K., Vilms, R. J., & Hamerman-Johnson, L. (2010). Universal bilirubin screening for severe
neonatal hyperbilirubinemia. Journal of perinatology, 30, S6-S15.
Canadian Paediatric Society. (2007). Guidelines for detection, management and prevention of
hyperbilirubinemia in term and late preterm infants (35 or more weeks’ gestation). Paediatrics and
Child Health, 12(5),1B-12B.
Cohen, S. M. (2006). Jaundice in the full-term newborn. Pediatric Nursing, 32(3), 202-208.
ECRI Institute. (2010). Identifying and managing jaundice in newborns. Healthcare Risk Control: Obstetrics
and Neonatal 10, Supplement A. Retrieved from
https://www.ecri.org/Documents/PSA/August_2010/ObNeo10.pdf
Engle, W. A. (2006). A recommendation for the definition of “late preterm” (near-term) and the birth
weight–gestational age classification system. Seminars in Perinatology, 30(1), 2-7. Retrieved from
http://www.sciencedirect.com.ezproxy.library.ubc.ca/science/article/pii/S0146000506000085
Harrison, S. L., Devine, S. G., Saunders, V. L., Smith, A. D., Buettner, P. G., & Nowak, M. J. (2013).
Changing the risky beliefs of post-partum women about therapeutic sun-exposure. Women and
Birth,26(3), 202-206. Retrieved from http://ac.elscdn.com.ezproxy.library.ubc.ca/S1871519213000395/1-s2.0-S1871519213000395main.pdf?_tid=2863f1b8-92ac-11e3-9beb00000aab0f26&acdnat=1392075566_c42954f3ae4d8cc49e3f995028e68ede
Harrison, S. L., Nikles, J., & Nowak, M. (2013). Don’t burn the baby: Advice from Australian nurses
recommending therapeutic sun exposure during infancy. Open journal of preventive medicine,
3(2), 212-218.
Keren, R., & Bhutani, V. (2007). Predischarge risk assessment for severe hyperbilirubinemia. NeoReviews,
8(2), e68.
Keren, R., Tremont, K., Luan, X., & Cnaan, A. (2009). Visual assessment of jaundice in term and late
preterm infants. Archives of Disease in Childhood -- Fetal & Neonatal Edition, 94(5), F317-22. doi:
10.1136/adc.2008.150714
Lease, M., & Whalen, B. (2010). Assessing jaundice in infants of 35-week gestation and greater. Current
Opinion in Pediatrics, 22(3), 352-365.
Mah, M. P., Clark, S. L., Akhigbe, E., Englebright, J., Frye, D. K., Meyers, J. A., . . . Shepard, A. (2010).
Reduction of severe hyperbilirubinemia after institution of predischarge bilirubin screening.
Pediatrics, 125(5), 1143-1148.
Makadia, D., Siddaiahgari, S. R., & Latha, M. S. (2013). Anti b cell targeted therapy for autoimmune
hemolytic anemia in an infant. Indian Journal of Pharmacology, 45(5), 526-527. Retrieved from
http://www.swetswise.com.ezproxy.library.ubc.ca/FullTextProxy/swproxy?url=http://www.medknow
.com/doi.asp?10.4103/02537613.117755&ts=1392012442694&cs=1291924573&userName=8900027.ipdirect&emCondId=89
00027&articleID=173218925&yevoID=99280204&titleID=98534&remoteAddr=142.103.160.110&h
ostType=PRO
Malwade, U. S., & Jardine, L. A. (2012). Home versus hospital‐based phototherapy for the treatment of
non‐haemolytic jaundice in infants more than 37 weeks gestation. The Cochrane Library. doi:
10.1002/14651858.CD010212
Mishra, S., Agarwal, R., Deorari, A. K., & Paul, V. K. (2008). "Jaundice in the newborns." The Indian
Journal of Pediatrics 75(2), 157-163.
National Institute for Health and Care Excellence. (2010). Neonatal jaundice. NICE clinical guideline, 98, 141. Retrieved from http://www.nice.org.uk/nicemedia/live/12986/48578/48578.pdf
Newman, T. (2009). Universal bilirubin screening, guidelines, and evidence. Pediatrics, 124(4),
Okwundu, C. I., Okoromah, C. A., & Shah, P. S. (2013). Cochrane review: Prophylactic phototherapy for
preventing jaundice in preterm or low birth weight infants. Evidence‐Based Child Health: A
Cochrane Review Journal, 8(1), 204-249. doi: 10.1002/ebch.1898
Perinatal Services BC. (2013). Newborn nursing care pathway. Newborn Guideline 13, Retrieved from
Http://www.perinatalservicesbc.ca/NR/rdonlyres/757B1BCE-E87C-4F79-840157156ED829B2/0/PSBC_Guideline_13_NewbornNursingCarePathway.pdf
Page 9 of 12
February 2014
Queensland Maternity and Neonatal Clinical Guidelines Program. (2012). Neonatal jaundice: prevention,
assessment and management. Queensland Maternity and Neonatal Clinical Guidelines, Retrieved
from http://www.health.qld.gov.au/qcg/documents/g_jaundice5-1.pdf
Stokowski, L. A. (2011). Fundamentals of phototherapy for neonatal jaundice. Advances in Neonatal Care,
11, S10-S21. Retrieved from http://ovidsp.tx.ovid.com.ezproxy.library.ubc.ca/sp3.11.0a/ovidweb.cgi?WebLinkFrameset=1&S=LGHAFPLJFODDGAMGNCNKCDFBIJLEAA00&ret
urnUrl=ovidweb.cgi%3f%26Full%2bText%3dL%257cS.sh.22.23%257c0%257c0014952520111000100003%26S%3dLGHAFPLJFODDGAMGNCNKCDFBIJLEAA00&directlink=http%3a%2f%2fgraphi
cs.tx.ovid.com%2fovftpdfs%2fFPDDNCFBCDMGFO00%2ffs046%2fovft%2flive%2fgv025%2f0014
9525%2f00149525-20111000100003.pdf&filename=Fundamentals+of+Phototherapy+for+Neonatal+Jaundice.&pdf_key=FPDDN
CFBCDMGFO00&pdf_index=/fs046/ovft/live/gv025/00149525/00149525-201110001-00003
Stokowski, L. A. (2011). Fundamentals of phototherapy for neonatal jaundice. Advances in Neonatal Care,
11, S10-S21. Retrieved from http://ovidsp.tx.ovid.com.ezproxy.library.ubc.ca/sp3.11.0a/ovidweb.cgi?WebLinkFrameset=1&S=LGHAFPLJFODDGAMGNCNKCDFBIJLEAA00&ret
urnUrl=ovidweb.cgi%3f%26Full%2bText%3dL%257cS.sh.22.23%257c0%257c0014952520111000100003%26S%3dLGHAFPLJFODDGAMGNCNKCDFBIJLEAA00&directlink=http%3a%2f%2fgraphi
cs.tx.ovid.com%2fovftpdfs%2fFPDDNCFBCDMGFO00%2ffs046%2fovft%2flive%2fgv025%2f0014
9525%2f00149525-20111000100003.pdf&filename=Fundamentals+of+Phototherapy+for+Neonatal+Jaundice.&pdf_key=FPDDN
CFBCDMGFO00&pdf_index=/fs046/ovft/live/gv025/00149525/00149525-201110001-00003
Szucs, K. A., & Rosenman, M. B. (2013). Family-Centered, Evidence-Based Phototherapy Delivery.
Pediatrics, 131(6), e1982-e1985. Retrieved from
http://pediatrics.aappublications.org.ezproxy.library.ubc.ca/content/131/6/e1982
Tuzun, F., Kumral, A., Duman, N., & Ozkan, H. (2013). Breast milk jaundice: Effect of bacteria present in
breast milk and infant feces. Journal of Pediatric Gastroenterol Nutrition, 56(3), 328-332.
Watson, R. L. (2009). Hyperbilirubinemia. Critical care nursing clinics of North America, 21(1), 97-120.
Wickremasinghe, A. C., Karon, B. S., Saenger, A. K., & Cook, W. J. (2012). Effect of universal neonatal
transcutaneous bilirubin screening on blood draws for bilirubin analysis and phototherapy usage.
Journal of Perinatology, 32(851), 852-855.
Willis , S., Hannon, P., & Scrimshaw , S. (2002). The impact of the maternal experience with a jaundiced
newbor on the breastfeeding relationship. The Journal Of Family Practice,51(5), 465. Retrieved
from http://web.b.ebscohost.com.ezproxy.library.ubc.ca/ehost/pdfviewer/pdfviewer?sid=8cef7a77c89c-46c5-bd1a-6ed215e1b955@sessionmgr115&vid=2&hid=112
Development committee members
•
•
•
Chelsea MacAulay
Sarika Rama
Thayanthi Tharmaratnam
Page 10 of 12
February 2014
Appendices
APPENDIX 1:
Potential Algorithm for management and follow-up according to to predischarge bilirubin measurement
(Lease & Whalen, 2010)
Page 11 of 12
February 2014
APPENDIX 2:
Guidelines for detection, management, and prevention of hyperbilirubinemia in term and late
preterm newborn infants (Canadian Paediatrics Society's Community Paediatrics Committee and the
College of Family Physicians of Canada)
APPENDIX 3:
Management of hyperbilirubinemia in Newborn Infant 35 or more weeks of gestation (American Academy of
Pediatrics, 2004)
APPENDIX 4:
Universal bilirubin screening for severe neonatal hyperbilirubinemia (Bhutani, 2010)
Page 12 of 12
February 2014